AURKB and acute myeloid leukemia: For example, the highly selective Aurora B kinase inhibitor barasertib (AZD1152) exhibited an overall response rate of 45% in phase I/II trials in patients with acute myelogenous leukaemia (AML) when combined with low-dose cytosine arabinoside (LDAC).23